You are viewing: US Immune Repertoire Sequencing Market analysis

The US Immune Repertoire Sequencing Market was valued at $87.6 Million in 2025 and projected to reach to $137.2 Million by 2030, representing a compound annual growth rate of 9.4%. The US Immune Repertoire Sequencing Market is poised for sustained growth through 2030, reaching $137.2 million as healthcare systems increasingly integrate genomic sequencing into clinical workflows.

US Immune Repertoire Sequencing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Immune Repertoire Sequencing Market Trends and Insights

  • The US market is driven by increasing adoption of precision medicine, rising prevalence of immunological disorders, and growing investment in genomic research infrastructure.
  • In the US, healthcare providers and research institutions are increasingly leveraging immune repertoire sequencing to develop personalized immunotherapies and advance vaccine development. The US market benefits from strong regulatory support, established reimbursement pathways, and a robust biotechnology ecosystem.
  • By 2030, the US is expected to maintain its position as a leading market for immune repertoire sequencing technologies, supported by continued innovation in sequencing platforms and expanding clinical applications.
  • The US healthcare system's emphasis on precision diagnostics and personalized treatment approaches continues to fuel demand for advanced sequencing capabilities..

Key Market Statistics

  • CAGR (2025-2030) 9.4% CAGR
  • Market Size, 2025 ~USD 87.6 Million
  • Forecast, 2030 ~USD 137.2 Million
  • Country US

US Immune Repertoire Sequencing Market Overview

Market Valuation :

The US Immune Repertoire Sequencing Market is valued at $87.6 million in 2025, with strong growth trajectory driven by advancing genomic technologies and increased clinical adoption across major healthcare institutions.

Precision Medicine Adoption :

US healthcare providers are increasingly leveraging immune repertoire sequencing for personalized treatment strategies, particularly in oncology and immunotherapy applications, supporting market expansion at 9.4% CAGR through 2030.

Research Infrastructure Investment :

Significant US government and private sector funding in genomic research infrastructure, including NIH initiatives and biotech investments, is accelerating the development and commercialization of immune sequencing platforms.

Immunological Disorder Prevalence :

Rising incidence of autoimmune diseases, immunodeficiencies, and cancer in the US population is driving demand for advanced diagnostic and monitoring tools, positioning immune repertoire sequencing as a critical clinical asset.

US Immune Repertoire Sequencing Market Dynamics

  • Key drivers include expanding applications in CAR-T cell therapy monitoring, personalized cancer immunotherapy, and infectious disease diagnostics.
  • Major US academic medical centers and specialized diagnostic laboratories are investing heavily in sequencing capabilities to enhance patient outcomes and competitive positioning. Regulatory support from the FDA, coupled with declining sequencing costs and improved bioinformatics platforms, will further accelerate market penetration.
  • The US market benefits from robust reimbursement frameworks, advanced healthcare infrastructure, and strong intellectual property protections that attract both established diagnostics companies and innovative biotech startups to develop next-generation immune profiling solutions..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • The US Immune Repertoire Sequencing Market is valued at $87.6 million in 2025 and will reach $137.2 million by 2030, representing a 9.4% CAGR.
    • The US market is driven by precision medicine adoption, immunological disorder prevalence, and substantial genomic research investments.
    • The US benefits from favorable regulatory frameworks and established reimbursement models that accelerate market growth.
    • By 2030, the US will lead in immune repertoire sequencing innovation, supported by advanced platforms and expanding clinical applications.

    Immune Repertoire Sequencing Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment TCR KITS (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 9.6% from 2025 to 2030
    Largest Segment ASSAY KITS & REAGENTS (Product)
    Market Size Base Year (Billions) ~USD 0.35 (2025)
    Revenue Forecast (Billions) ~USD 0.56 (2030)
    Segments Covered Product, Type

    US Immune Repertoire Sequencing Market Report Segmentation

    2 segment dimensions are covered across the global market.

    By Product

    • Assay Kits & Reagents
    • Instruments & Software

    By Type

    • Bcr Kits
    • Other Assay Kits & Reagents
    • Tcr Kits

    US: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES15.510.68.98.28.49.311.114.29.9
    OTHER END USERS9.26.35.24.84.95.46.48.29.3
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES23.115.913.412.512.714.2172210.4
    TOTAL47.832.827.525.52628.834.544.410

    US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES40.140.343.747.551.756.361.567.39
    OTHER END USERS252527.129.331.834.637.741.18.7
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES36.236.64043.84852.858.1649.9
    TOTAL101.3102110.8120.6131.5143.7157.3172.59.3

    Target Audience

    • Diagnostic & Sequencing Companies : In vitro diagnostics manufacturers and genomic sequencing firms need US market data to develop targeted product portfolios, establish pricing strategies, and identify clinical validation opportunities within American healthcare systems.
    • Pharmaceutical & Biotech Firms : Immunotherapy and oncology companies require detailed US market insights to support companion diagnostic development, clinical trial design, and commercialization strategies for precision medicine applications.
    • Healthcare Providers & Hospitals : US academic medical centers, cancer centers, and specialty hospitals need market intelligence to evaluate sequencing platform investments, assess clinical utility, and optimize immunotherapy patient selection protocols.
    • Investment & Venture Capital : Investors and venture firms targeting the US genomics sector require validated market sizing, growth projections, and competitive analysis to identify promising companies and assess portfolio company valuations.
    • Healthcare Policy & Government Agencies : US regulatory bodies, health agencies, and policy makers need market data to inform reimbursement decisions, clinical guideline development, and genomic medicine infrastructure planning at the national level.

    Key Companies in the US Immune Repertoire Sequencing Market

    CompanyHQOwnershipStrongest segments
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    PACBIOUnited StatesPublic CompanyLong-read sequencing instruments (Revio, Sequel, Vega),Long-read consumables (SMRT cells, library prep, binding and sequencing kits),Short-read sequencing (Onso and related consumables),
    OXFORD NANOPORE TECHNOLOGIES PLCUnited KingdomPublic CompanyPromethION (2/24/48) instruments and consumables,MinION Mk 1D and related consumables,GridION / GridION Q systems and consumables,
    10X GENOMICSUnited StatesPublic CompanyChromium single-cell instruments and consumables,Visium spatial instruments and consumables,Xenium in situ instruments and consumables,
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious-disease diagnostics,Oncology and sexual & reproductive health assays,
    AGILENT TECHNOLOGIESUnited StatesPublic CompanyLife Sciences and Diagnostics (instruments, reagents, genomics, pathology, CDMO, biomolecular analysis),Agilent CrossLab (services, consumables, software, asset management),Applied Markets (GC, MS, spectroscopy, vacuum, remarketed instruments),
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences (research and genomic tools),Diagnostics (clinical instruments and consumables),
    TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
    ADAPTIVE BIOTECHNOLOGIESUnited StatesPublic CompanyclonoSEQ MRD diagnostics,Life sciences research immunosequencing,Pharma and biotech drug discovery partnerships,
    PERSONALIS, INC.United StatesPublic CompanyPharma and biotech translational research / clinical trial services (ImmunoID NeXT and exome-based services),MRD and therapy monitoring (NeXT Personal, NeXT Personal Dx),Clinical tumor profiling and Dx (NeXT Dx and related tests),

    ILLUMINA, INC.

    Illumina, Inc. is a United States-based public company founded in 1998 that employs 8,625 people. The company operates in the life sciences and genomics sector.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. It is a major provider of analytical instruments, reagents, and laboratory services.

    PACBIO

    PacBio is a United States-based public company founded in 2000 with 485 employees. The company specializes in DNA sequencing technology and solutions.

    OXFORD NANOPORE TECHNOLOGIES PLC

    Oxford Nanopore Technologies PLC is a United Kingdom-based public company founded in 2005 with 1,316 employees. It develops nanopore-based DNA and RNA sequencing technologies.

    10X GENOMICS

    10X Genomics is a United States-based public company founded in 2012 with 1,178 employees. The company provides solutions for single-cell and spatial genomics analysis.

    QIAGEN

    QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees. It develops and manufactures molecular diagnostics and life sciences products.

    AGILENT TECHNOLOGIES

    Agilent Technologies is a United States-based public company founded in 1999 with 18,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.

    DANAHER CORPORATION

    Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees. It operates across multiple sectors including life sciences, diagnostics, and environmental solutions.

    TAKARA BIO INC.

    Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company develops and manufactures molecular biology reagents and biotechnology products.

    ADAPTIVE BIOTECHNOLOGIES

    Adaptive Biotechnologies is a United States-based public company founded in 2009 with 624 employees. The company develops immune-driven diagnostics and therapeutics using T-cell and B-cell receptor sequencing.

    PERSONALIS, INC.

    Personalis, Inc. is a United States-based public company founded in 2011 with 260 employees. The company offers precision medicine and genomic analysis services.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise US market valuation ($87.6M in 2025) and verified 9.4% CAGR projections through 2030, enabling accurate financial forecasting and investment decision-making for market participants.
    • Competitive Landscape Intelligence : Understand the US-specific competitive dynamics, key players, market share distribution, and emerging entrants to identify partnership opportunities and strategic positioning within the American healthcare ecosystem.
    • Regulatory & Reimbursement Insights : Access detailed analysis of FDA approval pathways, Medicare/insurance reimbursement trends, and US healthcare policy impacts specific to immune sequencing, reducing market entry risks and accelerating commercialization timelines.
    • Clinical Application Opportunities : Identify high-value US clinical segments including CAR-T monitoring, oncology immunotherapy, and autoimmune diagnostics with specific adoption rates and revenue potential by healthcare setting and specialty.
    • Technology & Infrastructure Trends : Gain actionable insights into US genomic infrastructure investments, sequencing platform preferences, bioinformatics adoption, and technology roadmaps to align product development and go-to-market strategies.

    Frequently asked questions

    What is the current size of the US Immune Repertoire Sequencing Market?

    The US Immune Repertoire Sequencing Market is valued at $87.6 million in 2025.

    What is the projected size of the US market by 2030?

    The US Immune Repertoire Sequencing Market is projected to reach $137.2 million by 2030.

    What is the growth rate of the US Immune Repertoire Sequencing Market?

    The US market is expanding at a compound annual growth rate of 9.4% from 2025 to 2030.

    What factors are driving growth in the US market?

    The US market is driven by precision medicine adoption, rising immunological disorder prevalence, strong regulatory support, and increased genomic research investments.

    Why is the US a leading market for immune repertoire sequencing?

    The US leads due to its robust biotechnology ecosystem, established reimbursement pathways, advanced healthcare infrastructure, and emphasis on personalized medicine.

    RESEARCH METHODOLOGY

    This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global IRS market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    The market for the companies offering IRS is arrived at by secondary data available through paid and unpaid sources, analyzing the product and service portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives. Secondary data was analyzed to arrive at the overall size of the global IRS market, which was validated through primary research.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global IRS market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biotechnology companies, and experts from the supply side, such as C-level and D-level executives and managers. These interviews were conducted across major regions: North America, Europe, the Asia Pacific, and the Rest of the World (including Latin America, the Middle East, and Africa). This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

    The following is a breakdown of the primary respondents:

    Immune Repertoire Sequencing Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the IRS market was estimated and validated through multiple approaches, such as the top-down and bottom-up approaches. These methods were also used extensively to estimate the size of various market subsegments.

    • The research methodology used to estimate the market size includes the following:
    • The key players in the immune repertoire sequencing market have been identified through extensive primary and secondary research.
    • The revenues generated from the immune repertoire sequencing businesses of leading players in product and service offerings were determined separately through primary and secondary research.
    • The sum of the product and service market was used to arrive at the total IRS global market size, which was further segmented into various segments.
    • All percentage shares, splits, and breakdowns for respective market segments were determined using secondary sources and verified through primary sources.  
    Immune Repertoire Sequencing Market

    Data Triangulation

    After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

    Market Definition

    Immune repertoire refers to the diverse collection of T-cell and B-cell receptors within the adaptive immune system, which enables pathogen recognition and targeted immune responses. The IRS market encompasses technologies, products, and services that analyze the diversity and functional dynamics of T-cell and B-cell receptor repertoires within the adaptive immune system.

    This market includes instruments, software, assays, kits, and reagents for immune receptor profiling, alongside presequencing, sequencing, and data analysis services that support research applications, drug discovery & development, and clinical diagnostics utilizing advanced methods such as NGS and PCR by various end users.

    Stakeholders

    • CDMOs & CROs
    • Pharmaceutical & Biopharmaceutical Companies
    • Academic & Research Institutes
    • Diagnostic Companies
    • Venture Capitalists & Investors
    • Market Research & Consulting Firms
    • Government & Regulatory Associations

    Report Objectives

    • To define, describe, and forecast the IRS market based on product, products technology, service workflow, application, product end user, service end user, and region.
    • To provide detailed information regarding the major factors influencing market growth (drivers, opportunities, and industry-specific challenges) along with the current trends
    • To strategically analyze micromarkets concerning their growth trends, prospects, and contributions to the total IRS market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the revenue of market segments with respect to six major regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
    • To profile key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments in the IRS market, such as service launches, agreements, partnerships, collaborations, mergers & acquisitions, and R&D activities
    • To track and analyze the impact of AI/Gen AI on the IRS market
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and service excellence strategy

     

    Get the Full Immune Repertoire Sequencing Market Report

    Full forecast, segment splits, and company analysis for all Immune Repertoire Sequencing Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status